Exclusive: SEC probe of Valeant began with review of short seller - sources


NEW YORK (Reuters) - A U.S. regulatory probe of Valeant Pharmaceuticals International Inc , disclosed by the company on Monday, is focused on the drugmaker's relationship with specialty pharmacy Philidor RX Services and was triggered by Valeant’s own request that regulators investigate a short seller's allegations, people familiar with the matter said.

view Reuters: Business